Toronto General Hospital-University Health Network

Toronto, Ontario M5G2N2

2 studies enrolling now · 16 studies all time

What they study most

Autosomal Dominant Polycystic Kidney Disease, Bile Duct Diseases, Bile Duct Obstruction, Candidemia, Chronic Genotype 1a or 1b HCV Infection, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Diabetic Kidney Disease, Diabetic Polyneuropathy, Fungal Infection, Fungemia, Hepatitis C Virus, Hepatitis C, Chronic

Studies at this site

• ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) — Recruiting now
• Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes — Recruiting now
• A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) — Running, not enrolling
• Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI). — Running, not enrolling
• Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy — Running, not enrolling
• Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031 — Stopped early
• Transthyretin Amyloidosis Outcome Survey (THAOS) — Completed
• Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry — Completed
• Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP — Completed
• SpyGlass™ Discover Percutaneous — Completed
• Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric — Withdrawn before enrolling
• Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH — Stopped early
• CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension — Completed
• Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) — Completed
• GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection — Completed
• Lidorestat (IDD 676) for the Treatment of Diabetic Neuropathy — Status unconfirmed